Pharsight

Lastacaft patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10617695 ALLERGAN Ophthalmic compositions containing alcaftadine
Mar, 2027

(3 years from now)

US8664215 ALLERGAN Ocular allergy treatments with alcaftadine
Dec, 2027

(4 years from now)

Lastacaft is owned by Allergan.

Lastacaft contains Alcaftadine.

Lastacaft has a total of 2 drug patents out of which 0 drug patents have expired.

Lastacaft was authorised for market use on 28 July, 2010.

Lastacaft is available in solution/drops;ophthalmic dosage forms.

Lastacaft can be used as use of lastacaft to temporary relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander.

The generics of Lastacaft are possible to be released after 23 December, 2027.

Drugs and Companies using ALCAFTADINE ingredient

Market Authorisation Date: 28 July, 2010

Treatment: Use of lastacaft to temporary relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of LASTACAFT before it's drug patent expiration?
More Information on Dosage

LASTACAFT family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic